125 related articles for article (PubMed ID: 19780241)
1. Breast cancer: review of platinum-based cooperative group trials.
Pegram M
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S2-9. PubMed ID: 19780241
[TBL] [Abstract][Full Text] [Related]
2. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
5. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
7. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Khasraw M; Bell R
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
[TBL] [Abstract][Full Text] [Related]
9. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
11. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
Montemurro F; Aglietta M
Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
[TBL] [Abstract][Full Text] [Related]
12. The platinum agents: a role in breast cancer treatment?
Crown JP
Semin Oncol; 2001 Feb; 28(1 Suppl 3):28-37. PubMed ID: 11301372
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based chemotherapy in metastatic breast cancer: current status.
Decatris MP; Sundar S; O'Byrne KJ
Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
[TBL] [Abstract][Full Text] [Related]
14. Assessing the role of platinum agents in aggressive breast cancers.
Sikov WM
Curr Oncol Rep; 2015 Feb; 17(2):3. PubMed ID: 25665554
[TBL] [Abstract][Full Text] [Related]
15. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
16. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
17. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
18. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
19. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Crown J; Pegram M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
[TBL] [Abstract][Full Text] [Related]
20. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]